BernheimV1, Hal, Corpus, bibRecord, 000182

VE-cadherin post-translational modifications : from molecular mechanisms to clinical applications : from molecular mechanisms to clinical applications

Identifieur interne : 000182 ( Hal/Corpus ); précédent : 000181; suivant : 000183

VE-cadherin post-translational modifications : from molecular mechanisms to clinical applications : from molecular mechanisms to clinical applications

Auteurs : Adama Sidibe

Source :

RBID : Hal:tel-00819876

Descripteurs français

mix :
- Angiogenèse, Endothélium vasculaire, Polyarthrite rhumatoide, Tyrosine kinase, VE-cadhérine.

English descriptors

mix :
- Angiogenesis, Phosphorylation, Rhumatoid arthritis, VE-cadherin, Vascular endothelium.

Abstract

The vascular endothelium barrier function is influenced by vascular endothelial cadherin (VE-cadherin) modifications such as its cytoplasmic tail tyrosine phosphorylation and its ecto-domain cleavage (sVE). The work reported herein was divided into two parts: 1- Study of VE-cadherin modifications and the mechanisms underlying these ones in the rheumatoid arthritis context. This work demonstrated that VE-cadherin is a target of TNFα, a highly important cytokine in rheumatoid arthritis (RA) pathogenesis. We found TNFα to induce sVE shedding in a Src kinase dependent manner, suggesting the involvement of phosphorylation mechanism in this process. In addition, this VE-cadherin cleavage requires matrix metalloproteinase activities such as that of MMP-2. Applying these fundamental data to clinical study showed that sVE was detected in sera of 63 RA patients and its titer was correlated with the disease activity. This finding suggests an obvious interest for assaying sVE in RA therapies. 2- Study of VE-cadherin tyrosine phosphorylation in a context of hormones-regulated angiogenesis during mouse estrous cycle. The results showed VE-cadherin phosphorylation at Y685 that was regulated along mouse estrous cycle allowing to proposing mouse estrous cycle as a physiological model for studying VE-cadherin phosphorylation in vivo. The analysis of VE-cadherin Y685F knock-in mice (VE-Y685F) showed that these mice exhibit a higher vascular permeability in uterus and ovaries and the skin small capillaries compared to wild-type animals. Moreover, VE-Y685F mice presented higher levels of soluble VE-cadherin compared to wild-type counterparts in two induced arthritis model. Altogether, sVE and VE-cadherin phosphorylation present an array of interests for RA therapies as well as developing new therapeutic tools in RA and other vascular diseases.

Url:

https://tel.archives-ouvertes.fr/tel-00819876

Links to Exploration step

Hal:tel-00819876

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">VE-cadherin post-translational modifications : from molecular mechanisms to clinical applications : from molecular mechanisms to clinical applications</title>
<title xml:lang="fr">Modifications post-traductionnelles de la VE-cadhérine : des mécanismes moléculaires aux applications cliniques</title>
<author><name sortKey="Sidibe, Adama" sort="Sidibe, Adama" uniqKey="Sidibe A" first="Adama" last="Sidibe">Adama Sidibe</name>
<affiliation><hal:affiliation type="laboratory" xml:id="struct-139730" status="VALID">          <idno type="RNSR">201119439L</idno>
          <orgName>Biologie du Cancer et de l'Infection</orgName>
          <orgName type="acronym">BCI - UMR S1036</orgName>
          <desc>            <address>              <addrLine>BIOLOGIE DU CANCER ET DE L'INFECTION : DES MÉCANISMES MOLÉCULAIRES AUX APPLICATIONS TECHNOLOGIQUES17 rue des martyrs 38054 Grenoble cedex 9</addrLine>
              <country key="FR"></country>
            </address>
          </desc>
          <listRelation>            <relation name="DRF/BIG" active="#struct-300016" type="direct"></relation>
            <relation name="U1036" active="#struct-303623" type="direct"></relation>
            <relation active="#struct-445543" type="direct"></relation>
          </listRelation>
        <tutelles><tutelle name="DRF/BIG" active="#struct-300016" type="direct"><org type="institution" xml:id="struct-300016" status="VALID">          <orgName>Commissariat à l'énergie atomique et aux énergies alternatives</orgName>
          <orgName type="acronym">CEA</orgName>
          <desc>            <address>              <addrLine>Centre de SaclayCentre de GrenobleCentre de Cadaracheetc</addrLine>
              <country key="FR"></country>
            </address>
            <ref type="url">http://www.cea.fr/</ref>
          </desc>
        </org>
</tutelle>
<tutelle name="U1036" active="#struct-303623" type="direct"><org type="institution" xml:id="struct-303623" status="VALID">          <idno type="IdRef">026388278</idno>
          <orgName>Institut National de la Santé et de la Recherche Médicale</orgName>
          <orgName type="acronym">INSERM</orgName>
          <desc>            <address>              <addrLine>101, rue de Tolbiac, 75013 Paris </addrLine>
              <country key="FR"></country>
            </address>
            <ref type="url">http://www.inserm.fr</ref>
          </desc>
        </org>
</tutelle>
<tutelle active="#struct-445543" type="direct"><org type="institution" xml:id="struct-445543" status="VALID">          <idno type="IdRef">188399275</idno>
          <orgName>Université Grenoble Alpes</orgName>
          <orgName type="acronym">UGA</orgName>
          <date type="start">2016-01-01</date>
          <desc>            <address>              <addrLine>CS 40700 - 38058 Grenoble cedex</addrLine>
              <country key="FR"></country>
            </address>
            <ref type="url">http://www.univ-grenoble-alpes.fr</ref>
          </desc>
        </org>
</tutelle>
</tutelles>
</hal:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">HAL</idno>
<idno type="RBID">Hal:tel-00819876</idno>
<idno type="halId">tel-00819876</idno>
<idno type="halUri">https://tel.archives-ouvertes.fr/tel-00819876</idno>
<idno type="url">https://tel.archives-ouvertes.fr/tel-00819876</idno>
<date when="2012-12-14">2012-12-14</date>
<idno type="wicri:Area/Hal/Corpus">000182</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">VE-cadherin post-translational modifications : from molecular mechanisms to clinical applications : from molecular mechanisms to clinical applications</title>
<title xml:lang="fr">Modifications post-traductionnelles de la VE-cadhérine : des mécanismes moléculaires aux applications cliniques</title>
<author><name sortKey="Sidibe, Adama" sort="Sidibe, Adama" uniqKey="Sidibe A" first="Adama" last="Sidibe">Adama Sidibe</name>
<affiliation><hal:affiliation type="laboratory" xml:id="struct-139730" status="VALID">          <idno type="RNSR">201119439L</idno>
          <orgName>Biologie du Cancer et de l'Infection</orgName>
          <orgName type="acronym">BCI - UMR S1036</orgName>
          <desc>            <address>              <addrLine>BIOLOGIE DU CANCER ET DE L'INFECTION : DES MÉCANISMES MOLÉCULAIRES AUX APPLICATIONS TECHNOLOGIQUES17 rue des martyrs 38054 Grenoble cedex 9</addrLine>
              <country key="FR"></country>
            </address>
          </desc>
          <listRelation>            <relation name="DRF/BIG" active="#struct-300016" type="direct"></relation>
            <relation name="U1036" active="#struct-303623" type="direct"></relation>
            <relation active="#struct-445543" type="direct"></relation>
          </listRelation>
        <tutelles><tutelle name="DRF/BIG" active="#struct-300016" type="direct"><org type="institution" xml:id="struct-300016" status="VALID">          <orgName>Commissariat à l'énergie atomique et aux énergies alternatives</orgName>
          <orgName type="acronym">CEA</orgName>
          <desc>            <address>              <addrLine>Centre de SaclayCentre de GrenobleCentre de Cadaracheetc</addrLine>
              <country key="FR"></country>
            </address>
            <ref type="url">http://www.cea.fr/</ref>
          </desc>
        </org>
</tutelle>
<tutelle name="U1036" active="#struct-303623" type="direct"><org type="institution" xml:id="struct-303623" status="VALID">          <idno type="IdRef">026388278</idno>
          <orgName>Institut National de la Santé et de la Recherche Médicale</orgName>
          <orgName type="acronym">INSERM</orgName>
          <desc>            <address>              <addrLine>101, rue de Tolbiac, 75013 Paris </addrLine>
              <country key="FR"></country>
            </address>
            <ref type="url">http://www.inserm.fr</ref>
          </desc>
        </org>
</tutelle>
<tutelle active="#struct-445543" type="direct"><org type="institution" xml:id="struct-445543" status="VALID">          <idno type="IdRef">188399275</idno>
          <orgName>Université Grenoble Alpes</orgName>
          <orgName type="acronym">UGA</orgName>
          <date type="start">2016-01-01</date>
          <desc>            <address>              <addrLine>CS 40700 - 38058 Grenoble cedex</addrLine>
              <country key="FR"></country>
            </address>
            <ref type="url">http://www.univ-grenoble-alpes.fr</ref>
          </desc>
        </org>
</tutelle>
</tutelles>
</hal:affiliation>
</affiliation>
</author>
</analytic>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="mix" xml:lang="en"><term>Angiogenesis</term>
<term>Phosphorylation</term>
<term>Rhumatoid arthritis</term>
<term>VE-cadherin</term>
<term>Vascular endothelium</term>
</keywords>
<keywords scheme="mix" xml:lang="fr"><term>Angiogenèse</term>
<term>Endothélium vasculaire</term>
<term>Polyarthrite rhumatoide</term>
<term>Tyrosine kinase</term>
<term>VE-cadhérine</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The vascular endothelium barrier function is influenced by vascular endothelial cadherin (VE-cadherin) modifications such as its cytoplasmic tail tyrosine phosphorylation and its ecto-domain cleavage (sVE). The work reported herein was divided into two parts: 1- Study of VE-cadherin modifications and the mechanisms underlying these ones in the rheumatoid arthritis context. This work demonstrated that VE-cadherin is a target of TNFα, a highly important cytokine in rheumatoid arthritis (RA) pathogenesis. We found TNFα to induce sVE shedding in a Src kinase dependent manner, suggesting the involvement of phosphorylation mechanism in this process. In addition, this VE-cadherin cleavage requires matrix metalloproteinase activities such as that of MMP-2. Applying these fundamental data to clinical study showed that sVE was detected in sera of 63 RA patients and its titer was correlated with the disease activity. This finding suggests an obvious interest for assaying sVE in RA therapies. 2- Study of VE-cadherin tyrosine phosphorylation in a context of hormones-regulated angiogenesis during mouse estrous cycle. The results showed VE-cadherin phosphorylation at Y685 that was regulated along mouse estrous cycle allowing to proposing mouse estrous cycle as a physiological model for studying VE-cadherin phosphorylation in vivo. The analysis of VE-cadherin Y685F knock-in mice (VE-Y685F) showed that these mice exhibit a higher vascular permeability in uterus and ovaries and the skin small capillaries compared to wild-type animals. Moreover, VE-Y685F mice presented higher levels of soluble VE-cadherin compared to wild-type counterparts in two induced arthritis model. Altogether, sVE and VE-cadherin phosphorylation present an array of interests for RA therapies as well as developing new therapeutic tools in RA and other vascular diseases.</div>
</front>
</TEI>
<hal api="V3">          <titleStmt>            <title xml:lang="en">VE-cadherin post-translational modifications : from molecular mechanisms to clinical applications : from molecular mechanisms to clinical applications</title>
            <title xml:lang="fr">Modifications post-traductionnelles de la VE-cadhérine : des mécanismes moléculaires aux applications cliniques</title>
            <author role="aut">              <persName>                <forename type="first">Adama</forename>
                <surname>Sidibe</surname>
              </persName>
              <idno type="halauthorid">1566107</idno>
              <affiliation ref="#struct-139730"></affiliation>
            </author>
            <editor role="depositor">              <persName>                <forename>ABES</forename>
                <surname>STAR</surname>
              </persName>
              <email type="md5">f5aa7f563b02bb6adbba7496989af39a</email>
              <email type="domain">abes.fr</email>
            </editor>
          </titleStmt>
          <editionStmt>            <edition n="v1" type="current">              <date type="whenSubmitted">2013-05-02 16:22:32</date>
              <date type="whenModified">2018-01-29 12:00:27</date>
              <date type="whenReleased">2013-05-03 11:34:25</date>
              <date type="whenProduced">2012-12-14</date>
              <date type="whenEndEmbargoed">2013-05-02</date>
              <ref type="file" target="https://tel.archives-ouvertes.fr/tel-00819876/document">                <date notBefore="2013-05-02"></date>
              </ref>
              <ref type="file" subtype="author" n="1" target="https://tel.archives-ouvertes.fr/tel-00819876/file/32766_SIDIBE_2012_archivage1.pdf">                <date notBefore="2013-05-02"></date>
              </ref>
            </edition>
            <respStmt>              <resp>contributor</resp>
              <name key="131274">                <persName>                  <forename>ABES</forename>
                  <surname>STAR</surname>
                </persName>
                <email type="md5">f5aa7f563b02bb6adbba7496989af39a</email>
                <email type="domain">abes.fr</email>
              </name>
            </respStmt>
          </editionStmt>
          <publicationStmt>            <distributor>CCSD</distributor>
            <idno type="halId">tel-00819876</idno>
            <idno type="halUri">https://tel.archives-ouvertes.fr/tel-00819876</idno>
            <idno type="halBibtex">sidibe:tel-00819876</idno>
            <idno type="halRefHtml">Sciences agricoles. Université de Grenoble, 2012. Français. 〈NNT : 2012GRENV051〉</idno>
            <idno type="halRef">Sciences agricoles. Université de Grenoble, 2012. Français. 〈NNT : 2012GRENV051〉</idno>
          </publicationStmt>
          <seriesStmt>            <idno type="stamp" n="STAR">STAR - Dépôt national des thèses électroniques</idno>
            <idno type="stamp" n="CEA">CEA - Commissariat à l'énergie atomique</idno>
            <idno type="stamp" n="IRTSV-BCI" p="IRTSV">Biologie du Cancer et de l'Infection (BCI)</idno>
            <idno type="stamp" n="UGA">HAL Grenoble Alpes</idno>
            <idno type="stamp" n="FDONZEL">CCSD - DONZEL</idno>
          </seriesStmt>
          <notesStmt></notesStmt>
          <sourceDesc>            <biblStruct>              <analytic>                <title xml:lang="en">VE-cadherin post-translational modifications : from molecular mechanisms to clinical applications : from molecular mechanisms to clinical applications</title>
                <title xml:lang="fr">Modifications post-traductionnelles de la VE-cadhérine : des mécanismes moléculaires aux applications cliniques</title>
                <author role="aut">                  <persName>                    <forename type="first">Adama</forename>
                    <surname>Sidibe</surname>
                  </persName>
                  <idno type="halauthorid">1566107</idno>
                  <affiliation ref="#struct-139730"></affiliation>
                </author>
              </analytic>
              <monogr>                <idno type="nnt">2012GRENV051</idno>
                <imprint>                  <date type="dateDefended">2012-12-14</date>
                </imprint>
                <authority type="institution">Université de Grenoble</authority>
                <authority type="school">École doctorale chimie et science du vivant (Grenoble)</authority>
                <authority type="supervisor">Isabelle Vilgrain</authority>
                <authority type="jury">Annie Andrieux [Président]</authority>
                <authority type="jury">Olivier Vittecoq [Rapporteur]</authority>
                <authority type="jury">Gilles Pages [Rapporteur]</authority>
                <authority type="jury">Olivier Chabre</authority>
                <authority type="jury">Ewa Ninio</authority>
              </monogr>
            </biblStruct>
          </sourceDesc>
          <profileDesc>            <langUsage>              <language ident="fr">French</language>
            </langUsage>
            <textClass>              <keywords scheme="author">                <term xml:lang="en">Rhumatoid arthritis</term>
                <term xml:lang="en">VE-cadherin</term>
                <term xml:lang="en">Angiogenesis</term>
                <term xml:lang="en">Vascular endothelium</term>
                <term xml:lang="en">Phosphorylation</term>
                <term xml:lang="fr">Angiogenèse</term>
                <term xml:lang="fr">Endothélium vasculaire</term>
                <term xml:lang="fr">Tyrosine kinase</term>
                <term xml:lang="fr">VE-cadhérine</term>
                <term xml:lang="fr">Polyarthrite rhumatoide</term>
              </keywords>
              <classCode scheme="halDomain" n="sdv.sa">Life Sciences [q-bio]/Agricultural sciences</classCode>
              <classCode scheme="halTypology" n="THESE">Theses</classCode>
            </textClass>
            <abstract xml:lang="en">The vascular endothelium barrier function is influenced by vascular endothelial cadherin (VE-cadherin) modifications such as its cytoplasmic tail tyrosine phosphorylation and its ecto-domain cleavage (sVE). The work reported herein was divided into two parts: 1- Study of VE-cadherin modifications and the mechanisms underlying these ones in the rheumatoid arthritis context. This work demonstrated that VE-cadherin is a target of TNFα, a highly important cytokine in rheumatoid arthritis (RA) pathogenesis. We found TNFα to induce sVE shedding in a Src kinase dependent manner, suggesting the involvement of phosphorylation mechanism in this process. In addition, this VE-cadherin cleavage requires matrix metalloproteinase activities such as that of MMP-2. Applying these fundamental data to clinical study showed that sVE was detected in sera of 63 RA patients and its titer was correlated with the disease activity. This finding suggests an obvious interest for assaying sVE in RA therapies. 2- Study of VE-cadherin tyrosine phosphorylation in a context of hormones-regulated angiogenesis during mouse estrous cycle. The results showed VE-cadherin phosphorylation at Y685 that was regulated along mouse estrous cycle allowing to proposing mouse estrous cycle as a physiological model for studying VE-cadherin phosphorylation in vivo. The analysis of VE-cadherin Y685F knock-in mice (VE-Y685F) showed that these mice exhibit a higher vascular permeability in uterus and ovaries and the skin small capillaries compared to wild-type animals. Moreover, VE-Y685F mice presented higher levels of soluble VE-cadherin compared to wild-type counterparts in two induced arthritis model. Altogether, sVE and VE-cadherin phosphorylation present an array of interests for RA therapies as well as developing new therapeutic tools in RA and other vascular diseases.</abstract>
            <abstract xml:lang="fr">La fonction de barrière de l'endothélium vasculaire est affectée par des modifications de la cadhérine des cellules endothéliales (VE-cadhérine) telles que la phosphorylation sur tyrosine dans son domaine cytoplasmique et le clivage de son domaine extracellulaire (sVE). Ce travail s'est articulé en deux parties : 1- Etude de ces modifications dans le contexte de la polyarthrite rhumatoïde (PR), et les mécanismes sous-tendus. Ce travail a permis de montrer que la VE-cadhérine est une cible du TNFα, une cytokine essentielle dans la PR, qui induit de la libération de sVE de façon dépendante de l'activité kinase de Src, suggérant l'implication d'un mécanisme de phosphorylation sur tyrosine dans ce processus. De plus, la VE-cadhérine est aussi la cible des protéases de la matrice extracellulaire telles que MMP-2. L'application de ces données fondamentales à la clinique a permis de montrer que sVE était retrouvée dans le sang de patients PR (n=63) et que son taux était corrélé à l'activité de la maladie. Ainsi, le dosage de sVE est d'intérêt dans la prise en charge des patients. 2-Etude de la phosphorylation de la VE-cadhérine dans un contexte d'angiogenèse hormono-régulée au cours du cycle ovarien chez la souris. Les résultats ont montré que le site Y685 de la VE-cadhérine est phosphorylé dans l'ovaire et l'utérus de souris de façon régulée pendant le cycle, ce qui permet de proposer ce modèle physiologique pour étudier la phosphorylation de la VE-cadhérine in vivo. L'analyse de souris knock-in Y685F de la VE-cadhérine (VE-Y685F) a montré que l'absence du site confère une perméabilité accrue dans l'ovaire et l'utérus mais aussi dans les petits capillaires de la peau. De plus, dans deux modèles d'induction d'arthrite, les souris VE-Y685F ont présenté un taux de sVE plus élevé que les contrôles. Au total, sVE et la phosphorylation de la VE-cadhérine ont un vaste champ d'application dans le traitement de la PR ainsi que pour le développement de nouvelles thérapies pouvant s'étendre à d'autres pathologies vasculaires.</abstract>
          </profileDesc>
        </hal>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Psychologie/explor/BernheimV1/Data/Hal/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000182 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Hal/Corpus/biblio.hfd -nk 000182 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Psychologie
   |area=    BernheimV1
   |flux=    Hal
   |étape=   Corpus
   |type=    RBID
   |clé=     Hal:tel-00819876
   |texte=   VE-cadherin post-translational modifications : from molecular mechanisms to clinical applications : from molecular mechanisms to clinical applications
}}

This area was generated with Dilib version V0.6.33.
Data generation: Mon Mar 5 17:33:33 2018. Site generation: Thu Apr 29 15:49:51 2021

	Serveur d'exploration Hippolyte Bernheim
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Hippolyte Bernheim

VE-cadherin post-translational modifications : from molecular mechanisms to clinical applications : from molecular mechanisms to clinical applications

VE-cadherin post-translational modifications : from molecular mechanisms to clinical applications : from molecular mechanisms to clinical applications

Source :

Descripteurs français

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri